207 related articles for article (PubMed ID: 30542701)
21. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
22. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
Weber JS; Vogelzang NJ; Ernstoff MS; Goodman OB; Cranmer LD; Marshall JL; Miles S; Rosario D; Diamond DC; Qiu Z; Obrocea M; Bot A
J Immunother; 2011 Sep; 34(7):556-67. PubMed ID: 21760528
[TBL] [Abstract][Full Text] [Related]
24. CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.
Anwar MY; Williams GR; Paluri RK
J Gastrointest Cancer; 2021 Mar; 52(1):1-10. PubMed ID: 32700185
[TBL] [Abstract][Full Text] [Related]
25. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
28. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Slovin SF
Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
[TBL] [Abstract][Full Text] [Related]
30. [Advances in prostate-specific membrane antigen targeted therapies for prostate cancer].
Wang W; Mo ZN
Zhonghua Nan Ke Xue; 2010 Jun; 16(6):547-51. PubMed ID: 20608362
[TBL] [Abstract][Full Text] [Related]
31. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
33. Antibody-drug conjugates targeting prostate-specific membrane antigen.
Olson WC; Israel RJ
Front Biosci (Landmark Ed); 2014 Jan; 19(1):12-33. PubMed ID: 24389170
[TBL] [Abstract][Full Text] [Related]
34. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
35. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.
Zuccolotto G; Fracasso G; Merlo A; Montagner IM; Rondina M; Bobisse S; Figini M; Cingarlini S; Colombatti M; Zanovello P; Rosato A
PLoS One; 2014; 9(10):e109427. PubMed ID: 25279468
[TBL] [Abstract][Full Text] [Related]
36. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
37. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
[TBL] [Abstract][Full Text] [Related]
38. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues.
Cunha AC; Weigle B; Kiessling A; Bachmann M; Rieber EP
Cancer Lett; 2006 May; 236(2):229-38. PubMed ID: 16046056
[TBL] [Abstract][Full Text] [Related]
39. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
[TBL] [Abstract][Full Text] [Related]
40. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy.
Gong MC; Chang SS; Watt F; O'Keefe DS; Bacich DJ; Uchida A; Bander NH; Reuter VE; Gaudin PB; Molloy PL; Sadelian M; Heston WD
Mol Urol; 2000; 4(3):217-22;discussion 223. PubMed ID: 11062377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]